Blue Earth Diagnostics Highlights Presentations on Fluciclovine F 18 and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

San Francisco, CA ( -- Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced upcoming presentations at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting, from October 23 – 28, 2020, to be held in a virtual format.

Presentations encompass the clinical use of Axumin® (fluciclovine F 18) injection positron emission tomography (PET) in recurrent prostate cancer, including a Late-Breaking Abstract Plenary Session presentation by Emory University. Information about an independent investigational study of 18F-fluciclovine PET in brain metastases will also be presented at the meeting. Details of selected oral and poster presentations by Blue Earth Diagnostics collaborators are listed below.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted.


Monday, October 26, 2020
Axumin (fluciclovine F 18) presentations

Title: LBA 1 Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer
Session Title: PL 01 - Plenary Session
Presenter: Ashesh Jani, MD, FASTRO, Emory University, Atlanta, Ga.
Presentation Time: 1:35 ‒ 1:45 PM ET
Presentation No.: LBA 1

Investigational 18F-fluciclovine presentation

Poster Title: 18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis from Tumor Progression in Brain Metastases Treated with Stereotactic Radiosurgery*
Session Title: PV 05 – Poster Q&A – Session 5
Presenter: Martin C. Tom, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
Presentation Time: 4:30 PM ET
Presentation No.: 3587

Wednesday, October 28, 2020
Axumin (fluciclovine F 18) presentations

Poster Title: Advanced Imaging Including the 18-F Fluciclovine PET-CT Is Instrumental In the Salvage Management of Prostate Cancer
Session Title: PV 07 – Poster Q&A – Session 7
Presenter: Max Chiu, MD, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Neb.
Presentation Time: 2:00 PM ET
Presentation No.: 4136

Poster Title: The Use of 18F-fluciclovine PET/CT in Prostate Cancer Diagnosis and Therapeutic Decision Making
Session Title: PV 07 – Poster Q&A – Session 7
Presenter: Alexandra Dreyfuss, MD, MS, Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.,
Presentation Time: 2:00 PM ET
Presentation No.: 4056

Blue Earth Diagnostics invites participants at the 2020 ASTRO Annual Meeting to attend the presentations above and to visit Blue Earth Diagnostics’ Commercial Product Showcase for Axumin (fluciclovine F 18) Injection in the Virtual Exhibit Hall. The company also has a Medical Affairs information booth at ASTRO, where attendees can learn about ongoing clinical trials. For full session details and scientific presentation listings, please see the ASTRO2020 online program.

Source: WIRE, BUSINESS. 2020. "Blue Earth Diagnostics Highlights Presentations On Axumin® (Fluciclovine F 18) And 18F-Fluciclovine At Upcoming ASTRO Annual Meeting". Businesswire.Com

Related Content:

18F-Fluciclovine Positron Emission Tomography in Men with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiotherapy: Results from LOCATE - Beyond the Abstract

Prostate Cancer Imaging Is Changing Rapidly – What More Should Be Done with Fluciclovine (Axumin®) PET/CT Imaging?